Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 16/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492329 | 0.84 | MAOB (0.58) | MAOBNAMPTS1PR3MCHR1HDAC1 | |
| SCHEMBL26255466 | 0.83 | NAMPT (0.58) | MAOBNAMPTHDAC1CYP2C9 | |
| SCHEMBL12327197 | 0.81 | MAOB (0.51) | MAOBNAMPTS1PR3MCHR1HDAC1 | |
| SCHEMBL18569900 | 0.81 | NAMPT (0.60) | MAOBNAMPTHDAC1CYP2C9 | |
| SCHEMBL359745 | 0.81 | TRIM33 (0.55) | MAOBNAMPTS1PR3MCHR1HDAC1 | |
| SCHEMBL20603245 | 0.80 | NAMPT (0.55) | MAOBNAMPTHDAC1CYP2C9 | |
| SCHEMBL173528 | 0.80 | MAOB (0.52) | MAOBNAMPTS1PR3MCHR1HDAC1 | |
| SCHEMBL20899964 | 0.79 | MAOB (0.50) | MAOBNAMPTS1PR3MCHR1HDAC1 | |
| SCHEMBL16220645 | 0.79 | NAMPT (0.61) | MAOBNAMPTHDAC1CYP2C9 | |
| SCHEMBL5401677 | 0.79 | NAMPT (0.60) | NAMPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112867715-B | 5-azaindazole derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2024-03-05 | — | — | CN | disclosed |
| EP-3870582-B1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2023-07-19 | — | — | EP | disclosed |
| EP-3870582-B1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2023-07-19 | — | — | EP | disclosed |
| CN-115551864-A | Substituted tricyclic amides, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20210380606-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2021-12-09 | — | — | US | disclosed |
| US-20210380606-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2021-12-09 | — | — | US | disclosed |
| EP-2580207-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154327-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380606-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | MAOB 406/4885NAMPT 613/4885S1PR3 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.